Global Microsclerotherapy
Treatment Market Restraints
Factors such as side effects and
high treatment costs are expected to restrain the global Microsclerotherapy
Treatment Market growth. According to the Journal of Phelbolymphology
(2017), around 1-10% patients reported matting and residual pigmentation as
complications post microsclerotherapy treatment. The treatments are expensive,
ranging from, US$ 600 to US$ 1,200, and the cost is dependent upon the size of the
vein and at least 2 to 6 treatment sessions are required with the interval of 4
to 6 weeks. The procedure is a little painful while compression bandage is to
be worn post operation for several weeks which can be uncomfortable to the
patients.
Microsclerotherapy is the method
used for the treatment of telangiectasia, which is a condition where broken
blood vessels near the surface or mucous membrane appears as pink or red lines
on the skin surface. Genetic and environmental factors contribute to
telangiectasia. Other factors that could cause telangiectasia are aging,
pregnancy, rosacea, overexposure to sunlight, and varicose veins. There is no
cure for this disorder, however, can be controlled by microsclerotherapy.
Microsclerotherapy involves
injecting a solution called 'sclerosant' using microneedles. The process
involves the injection of sclerosant in the affected veins, which destroys the
endothelium, it triggers thrombosis followed by fibrosis and this results in
the closing of the vessel. Sclerosant such as hypertonic saline solution,
polidocanol, tetradecyl sulphate, and chromated glycerin are used in
microsclerotherapy.
Some of the key manufacturers
operating in the global microsclerotherapy treatment market are Surgimedix,
Inc. (microneedles), Merz Pharma GmbH & Co. KGaA (Polidocanol), QOL Medical LLC (Ethanolamine
oleate), Mckesson Corporation (Sotradecol), Kreussler, Inc. (Compression
bandage), Provensis, ltd (Varithena), STD Pharmaceuticals Product Ltd.
(Fibrovein injections), Medtronic plc (microneedle), Teleflex incorporated
Vascular Solutions (Smartneedle vascular access system), and Boston Scientific
Corporation (Interject).
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3372
Microsclerotherapy Treatment
Market Drivers-
Leading manufacturers are
indulged in the development and commercialization of new sclerosants which
would be used in the treatment of varicose veins such as hypertonic saline,
sodium tetradecyl sulphate, and polidocanol. For instance, Medtronic Plc
launched a new product, Venaceal closure system in U.S., in November 2015. The
new product is non-invasive and uses a proprietary medical adhesive instead of
a sclerosant to seal the varicose veins and is effective for patients suffering
from varicose veins by eliminating the need for anesthesia, several injections,
and use of compression stockings post operation, thus reducing the disadvantages
caused by using sclerosants.
Moreover, in 2014, BTG
international Inc. launched varithena (polidocanol) which decreases the
symptoms, appearance of varicose veins as well as achiness, itching, and
swelling of the veins. Furthermore, manufacturers are also focused on inorganic
growth strategies such as mergers and acquisitions. For instance, in August
2019, Boston Scientific acquired BTG International, Inc as BTG manufactures and
commercialize products used in minimally invasive treatments used for targeting
cancer and other vascular diseases.
According the National Center for
Biotechnology Information (NCBI), 2019, 41% people in the U.S. suffer from
varicose veins and around 41% of women population and 50% of the men population
all over the world, over the age of 50 have telangiectasia. According to NCBI,
2018, lower limb varicose veins are very common and over 10 – 30% of the world
wide population suffers from telangiectasia. During the onset of periods and
pregnancy, most of the women are prone to telangiectasia. Other reasons are
standing and sitting for long periods of time, sitting cross legged, obesity,
and others. High incidence of telangiectasia is expected to boost the global
microsclerotherapy treatment market growth in the near future.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/microsclerotherapy-treatment-market-3372
Global Microsclerotherapy
Treatment Market Regional Analysis-
Highest incidences of
telangiectasia has been recorded in the Western Countries like Europe, America
and Australia and this disorder is most commonly observed in females as
compared to males. According to the International Journal of Pharmaceutical
Sciences and Research, (2018), High prevalence of varicose veins has been
recorded in U.S, Europe and some parts of Australia. According to the same
source, one third of the population worldwide is suffering from varicose veins,
out of which, around 73% females (especially during pregnancy) and 56% males
are suffering from varicose veins.
Most of the manufacturer’s
headquarters are located in U.S. and Europe like QOL Medical LLC, Mckesson
Corporation, Kreussler, Inc, and Teleflex Incorporated and Boston Scientific
Corporation. Therefore, introduction of existing as well as new treatment
options across North America and Europe is expected to drive the global
microsclerotherapy treatment market growth over the forecast period.
Global Microsclerotherapy Treatment
Market Key Players-
Key players operating in the
global microsclerotherapy treatment market are Surgimedix, Inc., Merz Pharma
GmbH & Co. KGaA, QOL Medical LLC, McKesson Corporation, Kreussler, Inc.,
Provensis, ltd, STD Pharmaceuticals Product Ltd., Medtronic plc, Teleflex Incorporated,
and Boston Scientific Corporation.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3372
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment